Brandenburg Kapital - News about Adrenomed AG
AdrenoMed receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
Hennigsdorf/Berlin - april 2024. AdrenoMed AG, a company focused on the integrity and barrier function of blood vessels (vascular integrity), announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate enibarcimab,. The antibody enibarcimab is thus recognized as an innovative, biomarker-based treatment for septic shock that addresses the unmet medical need in this very serious disease with a high mortality rate.
Using AdrenoMed's precision medicine approach, treatment of patients with septic shock with enibarcimab resulted in an improvement in organ dysfunction and a relevant reduction in all-cause mortality at day 28 from 24% to 8% in the patient population defined in a medical trial.
Brandenburg Kapital GmbH has been supporting the company since 2014.
Read the complete article here:
https://adrenomed.com/2024-04-10-adrenomed-fda-fast-track-enibarcimab/
About AdrenoMed
AdrenoMed AG is a German, privately financed, clinical-stage biopharmaceutical company. AdrenoMed's mission is to save vascular integrity in order to save the lives of critically ill patients with limited treatment options. The company was founded in 2009 by a management team with decades of experience in the field of sepsis as well as in-depth knowledge of diagnostics and drug development.
For more information, please visit: www.brandenburg-kapital.de and www.adrenomed.com